Acceptability of a Hypothetical Zika Vaccine among Women from Colombia and Spain Exposed to ZIKV: A Qualitative Study.

dc.contributor.authorMarbán Castro, Elena
dc.contributor.authorVillén Gonzalvo, Ana
dc.contributor.authorEnguita Fernàndez, Cristina
dc.contributor.authorRomero Acosta, Kelly Carolina
dc.contributor.authorMarín Cos, Anna
dc.contributor.authorArrieta, Germán J.
dc.contributor.authorMáttar, Salim
dc.contributor.authorMenéndez, Clara
dc.contributor.authorMaixenchs, Maria
dc.contributor.authorBardají, Azucena
dc.date.accessioned2022-04-19T07:59:31Z
dc.date.available2022-04-19T07:59:31Z
dc.date.issued2020
dc.date.updated2022-04-08T18:00:46Z
dc.description.abstractZika virus (ZIKV) can cause pregnancy loss and congenital Zika syndrome, among other poor health outcomes. The ZIKV epidemic in 2015-2017 disproportionately affected pregnant women in poor-resource settings. We aimed to understand perceptions and attitudes towards a hypothetical ZIKV vaccine, women's willingness to be vaccinated, and potential barriers and facilitators for vaccine acceptance in 1) migrant women living in Spain who travelled to their countries of origin and were diagnosed with ZIKV infection during pregnancy, and their healthcare providers, and 2) women living in Colombia who delivered a child with microcephaly. An exploratory qualitative study based on phenomenology and grounded theory was conducted. Data were collected through in-depth, paired and semi-structured interviews. Overall, women from both sites were willing to receive a hypothetical ZIKV vaccine. However, some expressed concerns of being vaccinated during pregnancy, yet they would accept it if the vaccine was recommended by a healthcare professional they trust. Main fears towards vaccination were related to vaccine safety and potential adverse effects on child's health. Women reported feeling hesitant to participate in a ZIKV vaccine trial. These results may contribute to guiding the effective delivery of future ZIKV vaccines among populations most at risk and particularly vulnerable.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2076-393X
dc.identifier.pmid33022907
dc.identifier.urihttps://hdl.handle.net/2445/184994
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.3390/vaccines8040580
dc.relation.ispartofVaccines, 2020, vol. 8, num. 4
dc.relation.urihttp://dx.doi.org/ 10.3390/vaccines8040580
dc.rightscc by (c) Marbán Castro, Elena et al, 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationMalalties víriques
dc.subject.classificationVacunes antivíriques
dc.subject.otherVirus diseases
dc.subject.otherViral vaccines
dc.titleAcceptability of a Hypothetical Zika Vaccine among Women from Colombia and Spain Exposed to ZIKV: A Qualitative Study.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Marban_E_Vaccines_Basel_2020.pdf
Mida:
281.69 KB
Format:
Adobe Portable Document Format